South African Journal of Oncology | |
Chronic myeloid leukaemia in the South African public health setting: Are we reaching the European LeukemiaNet targets for frontline therapy? | |
ARTICLE | |
Tshifhiwa B. Sikhipha1  Gina Joubert2  Claire L. Barrett1  Christopher D. Viljoen3  Shivani Dhar1  Jacques L.R. Malherbe1  | |
[1] Department of Internal Medicine, Faculty of Health Sciences, University of the Free State;Department of Biostatistics, Faculty of Health Sciences, University of the Free State;Department of Haematology and Cell Biology, Faculty of Health Sciences, University of the Free State | |
关键词: chronic myeloid leukemia; CML; outcomes; frontline therapy; tyrosine kinase inhibitors; imatinib.; | |
DOI : 10.4102/sajo.v4i0.158 | |
学科分类:工业工程学 | |
来源: AOSIS | |
【 摘 要 】
Background: Successful therapy of chronic myeloid leukaemia (CML) relies on close monitoring of patients’ response to therapy using the standardised real-time quantitative polymerase chain reaction (RQ-PCR) or fluorescent in situ hybridisation (FISH) at 3, 6 and 12 months. The European LeukemiaNet has published recommended therapeutic targets for frontline therapy at specific time points. Imatinib, a tyrosine kinase inhibitor, is used for the frontline treatment of chronic and accelerated phase CML in our setting. Aim: The aim of this study was to evaluate treatment response of patients with CML in chronic or accelerated phase treated with imatinib during the first 2 years of therapy. Setting: Universitas Academic Hospital, South Africa. Methods: In this analytical cohort study, a retrospective file review of all chronic and accelerated phase CML diagnosed between 2009 and 2016, who were initiated on imatinib as front-line therapy, was performed. Clinical and laboratory data were collected for different time intervals as recommended by European LeukemiaNet guidelines. Results: Thirty-seven patients met the inclusion criteria. An optimal response was obtained in 82.6%, 54.2%, 50.0% and 66.7% of patients at 3, 6, 12 and 18 months, respectively. Conclusion: The patient outcomes were comparable with other published studies, with two-thirds of patients achieving an optimal response at 18 months. It is important, however, that factors contributing to suboptimal responses in the remaining third of patients should be explored.
【 授权许可】
CC BY
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202106100003564ZK.pdf | 678KB | download |